MedTrace Logo

PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

NCT03850522 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-04-15

No results posted yet for this study

Summary

This study is evaluating a new vaccine against PD-L1 as a possible treatment for high-risk smoldering multiple myeloma.

Conditions

  • Smoldering Multiple Myeloma

Interventions

BIOLOGICAL

PD-L1 peptide

PD-L1 peptide (100 micrograms) emulsified with the adjuvant Montanide ISA-51 given subcutaneously 10 times every second week over the course of 26 weeks including a five-week break.

Sponsors & Collaborators

  • IO Biotech

    collaborator INDUSTRY

  • Lene Meldgaard Knudsen

    lead OTHER

Principal Investigators

  • Nicolai Jørgensen, MD · Department of Hematology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-18
Primary Completion
2021-03-10
Completion
2021-03-10

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03850522 on ClinicalTrials.gov